Crizotinib

Anaplastic Large Cell Lymphoma

PfizerSmall moleculePhase 4 / ApprovedActive

BBB

75/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 61/ 100
Competitive Position: 95/ 100

Competitive context

49 Active assets in the Anaplastic Large Cell Lymphoma cohort.

Asset / Sponsor	Phase	Rating
(+)-VINCRISTINE Seagen Inc.	Phase 4	BBB
Inno-206 City of Hope Medical Center	Phase 4	BBB
Brentuximab Vedotin Seagen Inc.	Phase 3	BBB
Cyclophosphamide National Cancer Institute (NCI)	Phase 4	BBB
Ifosfamide National Cancer Institute (NCI)	Phase 4	BB

View all 50 →

Same molecule, other indications

Crizotinib is also rated in:

inflammatory myofibroblastic tumorDormant

BB

Indicative ·

69 / 100

ALK-positive anaplastic large cell lymphomaDormant

BB

Indicative ·

68 / 100

non-small cell lung carcinomaDormant

BB

Indicative ·

66 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.